News

Biomea Fusion Presents New Preclinical And Clinical Data On Icovamenib At The 85Th Scientific Sessions Of The American Diabetes Association (ADA)
In a rodent model of type 2 diabetes (T2D), icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and b ...
manilatimes2d
Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA) | The ... - The Manila Times
Icovamenib's proposed mechanism of action in diabetes is to enable the proliferation, preservation, and reactivation of a patient's own healthy, ... the potential of icovamenib as a treatment for T1D ...